160/4.5 mcg BDF single inhaler therapy vs current best practice
Non‐fatal serious adverse events · adults with asthma not well controlled on ICS
160/4.5 mcg BDF single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with current best practice (low certainty).
1 finding from 1 review
- Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including… 2013 · Cochrane Headline outcomes onlyOR 1.2 [0.9, 1.6]8 studies · 8841 participantsLow